tbuckley/cabot-search huggingface dataset:
Dietary, Cultural, and Pathogens-Related Selective Pressures Shaped Differential Adaptive Evolution among Native Mexican Populations
Authors: Claudia Ojeda-Granados, Paolo Abondio, Alice Setti, Stefania Sarno, Guido Alberto Gnecchi-Ruscone, Eduardo González-Orozco, Sara De Fanti, Andres Jiménez-Kaufmann, Héctor Rangel-Villalobos, Andrés Moreno-Estrada, Marco Sazzini
Journal: Molecular Biology and Evolution (2021)

Native American genetic ancestry has been remarkably implicated with increased risk of diverse health issues in several Mexican populations, especially in relation to the dramatic changes in environmental, dietary, and cultural settings they have recently undergone. In particular, the effects of these ecological transitions and Westernization of lifestyles have been investigated so far predominantly on Mestizo individuals. Nevertheless, indigenous groups, rather than admixed Mexicans, have plausibly retained the highest proportions of genetic components shaped by natural selection in response to the ancient milieu experienced by Mexican ancestors during their pre-Columbian evolutionary history. These formerly adaptive variants have the potential to represent the genetic determinants of some biological traits that are peculiar to Mexican people, as well as a reservoir of loci with possible biomedical relevance. To test such a hypothesis, we used genome-wide genotype data to infer the unique adaptive evolution of Native Mexican groups selected as reasonable descendants of the main pre-Columbian Mexican civilizations. A combination of haplotype-based and gene-network analyses enabled us to detect genomic signatures ascribable to polygenic adaptive traits plausibly evolved by the main genetic clusters of Mexican indigenous populations to cope with local environmental and/or cultural conditions. Some of these adaptations were found to play a role in modulating the susceptibility/resistance of these groups to certain pathological conditions, thus providing new evidence that diverse selective pressures have contributed to shape the current biological and disease-risk patterns of present-day Native and Mestizo Mexican populations.
Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis
Authors: Seo Hee Choi, Chai Hong Rim, In-Soo Shin, Won Sup Yoon, Woong Sub Koom, Jinsil Seong
Journal: Liver Cancer (2021)

The benefits of adjuvant radiotherapy (ART) for extrahepatic cholangiocarcinoma are uncertain largely because existing publications lack clear comparisons between ART and non-ART arms.PubMed, Medline, Embase, and the Cochrane library were systematically searched until December 2020. The primary endpoint was overall survival (OS). Sensitivity analysis was performed for studies with reliable comparability (i.e., no favorable prognosticators in the ART arm that could skew the data).Twenty-three studies involving 1,731 patients with extrahepatic cholangiocarcinoma were reviewed. The overall median of all median prescribed doses was 50.4 Gy; brachytherapy or an intraoperative boost of 10-21 Gy was applied in 5 studies. The pooled 1-, 3-, and 5-year OS rates in the non-ART and ART arms were 69.2% versus 81.0%, p = 0.035; 34.3% versus 44.7%, p = 0.025; 25.6% versus 31.7%, p = 0.115, respectively. The corresponding pooled locoregional recurrence rates were 52.1% versus 34.9% (p = 0.014). The pooled rate of grade ≥3 gastrointestinal complications was 9.8%. Sensitivity analysis performed on 14 eligible studies showed that the ART arms had a lower pooled R0 rate (36.8% vs. 63.2%, p = 0.02) and a higher rate of positive lymph nodes (47.4% vs. 34.9%, p = 0.08). The pooled 1-, 3-, and 5-year OS rates in the non-ART versus ART arms of the selected studies were 78.2% versus 84.9%, p = 0.143; 38.5% versus 49.2%, p = 0.026; and 27.8% versus 34.5%, p = 0.11, respectively.ART was shown to improve OS in all studies and in those selected for their reliable comparability.
Corrigendum to “Exosomes as drug delivery vehicles for Parkinson's disease therapy” [Journal of Controlled Release 207, (2015) 18–30]
Authors: Matthew J. Haney, Natalia L. Klyachko, Yuling Zhao, Richa Gupta, Evgeniya G. Plotnikova, Zhijian He, Tejash Patel, Aleksandr Piroyan, Marina Sokolsky, Alexander V. Kabanov, Elena V. Batrakova
Journal: Journal of Controlled Release (2021)
Functional and evolutionary parallels between birdsong and human musicality
Authors: Kate T Snyder, Nicole Creanza
Journal: Behavioral and Brain Sciences (2021)

Abstract Here, we compare birdsong and human musicality using insights from songbird neuroethology and evolution. For example, neural recordings during songbird duetting and other coordinated vocal behaviors could inform mechanistic hypotheses regarding human brain function during music-making. Furthermore, considering songbird evolution as a model system suggests that selection favoring certain culturally transmitted behaviors can indirectly select for associated underlying neural functions.
104P Matching-adjusted indirect comparison for treatment of NTRK fusion cancer with larotrectinib versus entrectinib
Authors: J. Garcia-Foncillas, C. Bokemeyer, A. Italiano, K. Keating, N. Paracha, M. Fellous, M. Marian, M. Fillbrunn, W. Gao, R. Ayyagari, U.N. Lassen
Journal: Annals of Oncology (2021)
464P Exome sequencing of ctDNA portrays the mutational landscape of patients with relapsing colon cancer and indicates new actionable targets
Authors: N. Tarazona, J. Martín-Arana, R. Tébar-Martínez, F. Gimeno-Valiente, V. Gambardella, M. Huerta Alvaro, C. Martínez-Ciarpaglini, C. Alfaro-Cervello, M. Cabeza-Segura, B. García-Micó, S. Moragón, M. Tapia, J.A. Carbonell-Asins, P. Rentero-Garrido, S. Zuñiga, S. Roselló, T. Fleitas, J. Castillo, D. Roda Perez, A. Cervantes
Journal: Annals of Oncology (2021)
281P Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases
Authors: G. Griguolo, A. Tosi, M.V. Dieci, S. Fineberg, A. Ventura, M. Bottosso, L. Bauchet, F. Miglietta, J. Jacob, V. Rossi, V. Rigau, W. Jacot, P.F. Conte, A. Rosato, A. Darlix, V. Guarneri
Journal: Annals of Oncology (2021)
439P Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study
Authors: J.H. Strickler, L-I. Hsu, K. DeBusk, P. Wright, M. Stecher, M. Siadak, M.C. Palanca-Wessels, J. Yu, N. Zhang, C.R. Espenschied, K. Lang, T. Bekaii-Saab
Journal: Annals of Oncology (2021)
Lung function, airway and peripheral basophils and eosinophils are associated with molecular pharmacogenomic endotypes of steroid response in severe asthma
Authors: Alvin T Kho, Michael J McGeachie, Jiang Li, Robert P Chase, Sami S Amr, Annette T Hastie, Gregory A Hawkins, Xingnan Li, Geoffrey L Chupp, Deborah A Meyers, Eugene R Bleecker, Scott T Weiss, Kelan G Tantisira
Journal: Thorax (2021)

Asthma is a complex disease with heterogeneous expression/severity. There is growing interest in defining asthma endotypes consistently associated with different responses to therapy, focusing on type 2 inflammation (Th2) as a key pathological mechanism. Current asthma endotypes are defined primarily by clinical/laboratory criteria. Each endotype is likely characterised by distinct molecular mechanisms that identify optimal therapies.We applied unsupervised (without a priori clinical criteria) principal component analysis on sputum airway cells RNA-sequencing transcriptomic data from 19 asthmatics from the Severe Asthma Research Program at baseline and 6-8 weeks follow-up after a 40 mg dose of intramuscular corticosteroids. We investigated principal components PC1, PC3 for association with 55 clinical variables.PC3 was associated with baseline Th2 clinical features including blood (rank-sum p=0.0082) and airway (rank-sum p=0.0024) eosinophilia, FEV1 change (Kendall tau-b R=-0.333 (-0.592 to -0.012)) and follow-up FEV1 albuterol response (Kendall tau-b R=0.392 (0.079 to 0.634)). PC1 with blood basophlia (rank-sum p=0.0191). The top 5% genes contributing to PC1, PC3 were enriched for distinct immune system/inflammation ontologies suggesting distinct subject-specific clusters of transcriptomic response to corticosteroids. PC3 association with FEV1 change was reproduced in silico in a comparable independent 14-subject (baseline, 8 weeks after daily inhaled corticosteroids (ICS)) airway epithelial cells microRNAome dataset.Transcriptomic PCs from this unsupervised methodology define molecular pharmacogenomic endotypes that may yield novel biology underlying different subject-specific responses to corticosteroid therapy in asthma, and optimal personalised asthma care. Top contributing genes to these PCs may suggest new therapeutic targets.
Abstract 17340: Disparities in Wait Times for Heart Transplant by Racial and Ethnic Minorities
Authors: Anuradha Lala, Bart S Ferket, John Rowland, Francis D Pagani, Annetine C Gelijns, Alan J Moskowitz, Carol R Horowitz, Sean P Pinney, Emilia Bagiella, Donna M Mancini
Journal: Circulation (2018)

Introduction: Although wait times vary widely across geographic regions and blood type under the current allocation system, it is unclear if minority patients have longer waitlist times. Hypothesis: We hypothesized that racial/ethnic minority patients experience longer wait times to transplant, even after accounting for age, gender, blood type, heart failure severity defined by UNOS status, and region. Methods: Patients listed for first transplant from 2005-2016 in the UNOS database were analyzed by racial/ethnic groups: African-American (AA), Hispanic, White (Non-Hispanic) and Other. We estimated median time to transplant for each group by year of listing using cumulative incidence functions and accounted for competing risks of waitlist mortality and delisting. For 2015-2016, we performed multivariable cause-specific Cox regression modeling accounting for age, gender, UNOS status urgency (status 1A, 1B, 2, 7) ABO blood type, and region by organ procurement organization. The reference population was Whites. Results: A total of 36,801 patients (21.5% AA, 7.8% Hispanic, 4.0% Other and 66.6% White) were available for analysis. Since 2005, the proportion of AAs on the waitlist has increased slightly, while the proportion of Whites has decreased. Wait times increased to a peak in 2014 for all ethnic/racial groups, but were disproportionally increased for AAs. In 2015-2016 this disparity persisted but was less pronounced compared to prior years. ( Figure ) After multivariable adjustment, the Hazard Ratio for time to transplant in AAs was 0.90 (95% CI 0.83 – 0.96) compared to Whites, with no prolonged time to transplant for other minorities. Conclusions: AAs experience disproportionally long wait times for heart transplant, which could not be explained by traditional determinants of time to transplant. How the new allocation system implemented in 2018 will impact this disparity should be a focus for ongoing population health research.
1441O Patient-reported outcomes in cancer patients newly diagnosed with brain metastases
Authors: G.L. Astrup, S. Kaasa, N.K. Aass, M.J. Hjermstad, T. Lundeby, R. van Helvoirt, J-Å. Lund, Ø. Paulsen, O.E. Yri
Journal: Annals of Oncology (2021)
Antibody-engineered red blood cell interface for high-performance capture and release of circulating tumor cells
Authors: Haicong Shen, Rui Su, Jiao Peng, Lin Zhu, Kunyue Deng, Qi Niu, Yanling Song, Liu Yang, Lingling Wu, Zhi Zhu, Chaoyong Yang
Journal: Bioactive Materials (2021)

Circulating tumor cells (CTCs), as important liquid biopsy target, can provide valuable information for cancer progress monitoring and individualized treatment. However, current isolation platforms incapable of balancing capture efficiency, specificity, cell viability, and gentle release have restricted the clinical applications of CTCs. Herein, inspired by the structure and functional merits of natural membrane interfaces, we established an antibody-engineered red blood cell (RBC-Ab) affinity interface on microfluidic chip for high-performance isolation and release of CTCs. The lateral fluidity, pliability, and anti-adhesion property of the RBC microfluidic interface enabled efficient CTCs capture (96.5%), high CTCs viability (96.1%), and high CTCs purity (average 4.2-log depletion of leukocytes). More importantly, selective lysis of RBCs by simply changing the salt concentration was utilized to destroy the affinity interface for efficient and gentle release of CTCs without nucleic acid contamination. Using this chip, CTCs were successfully detected in colon cancer samples with 90% sensitivity and 100% specificity (20 patients and 10 healthy individuals). After the release process, KRAS gene mutations of CTCs were identified from all the 5 cancer samples, which was consistent with the results of tissue biopsy. We expect this RBC interface strategy will inspire further biomimetic interface construction for rare cell analysis.
1781P Feasibility of an automated data solution for Binary Alignment Map (BAM) files generated through next generation sequencing (NGS) of circulating tumor DNA (ctDNA)
Authors: L. Pellizzari, N. Rossi, M. Verardo, R. Spizzo, B. Belletti, C. Piazza, F. Puglisi, L. Gerratana
Journal: Annals of Oncology (2021)
Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
Authors: Congcong Zhang, Jasmin Röder, Anne Scherer, Malena Bodden, Jordi Pfeifer Serrahima, Anita Bhatti, Anja Waldmann, Nina Müller, Pranav Oberoi, Winfried S Wels
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Natural killer group 2D (NKG2D) is an activating receptor of natural killer (NK) cells and other lymphocytes that mediates lysis of malignant cells through recognition of stress-induced ligands such as MICA and MICB. Such ligands are broadly expressed by cancer cells of various origins and serve as targets for adoptive immunotherapy with effector cells endogenously expressing NKG2D or carrying an NKG2D-based chimeric antigen receptor (CAR). However, shedding or downregulation of NKG2D ligands (NKG2DL) can prevent NKG2D activation, resulting in escape of cancer cells from NKG2D-dependent immune surveillance. Methods To enable tumor-specific targeting of NKG2D-expressing effector cells independent of membrane-anchored NKG2DLs, we generated a homodimeric recombinant antibody which harbors an N-terminal single-chain fragment variable (scFv) antibody domain for binding to NKG2D, linked via a human IgG 4 Fc region to a second C-terminal scFv antibody domain for recognition of the tumor-associated antigen ErbB2 (HER2). The ability of this molecule, termed NKAB-ErbB2, to redirect NKG2D-expressing effector cells to ErbB2-positive tumor cells of different origins was investigated using peripheral blood mononuclear cells, ex vivo expanded NK cells, and NK and T cells engineered with an NKG2D-based chimeric receptor. Results On its own, bispecific NKAB-ErbB2 increased lysis of ErbB2-positive breast carcinoma cells by peripheral blood-derived NK cells endogenously expressing NKG2D more effectively than an ErbB2-specific IgG 1 mini-antibody able to induce antibody-dependent cell-mediated cytotoxicity via activation of CD16. Furthermore, NKAB-ErbB2 synergized with NK-92 cells or primary T cells engineered to express an NKG2D-CD3ζ chimeric antigen receptor (NKAR), leading to targeted cell killing and greatly enhanced antitumor activity, which remained unaffected by soluble MICA known as an inhibitor of NKG2D-mediated natural cytotoxicity. In an immunocompetent mouse glioblastoma model mimicking low or absent NKG2DL expression, the combination of NKAR-NK-92 cells and NKAB-ErbB2 effectively suppressed outgrowth of ErbB2-positive tumors, resulting in treatment-induced endogenous antitumor immunity and cures in the majority of animals. Conclusions Our results demonstrate that combining an NKAB antibody with effector cells expressing an activating NKAR receptor represents a powerful and versatile approach to simultaneously enhance tumor antigen-specific as well as NKG2D-CAR and natural NKG2D-mediated cytotoxicity, which may be particularly useful to target tumors with heterogeneous target antigen expression.
1751P Real-world study of REarranged during Transfection [RET] testing in patients [pts] with medullary thyroid cancer [MTC] in Europe [EU5]
Authors: R. Williams, L.M. Hess, T. Puri, M-H. Jen, M. Kostikas, A. Rider, U. Kiiskinen
Journal: Annals of Oncology (2021)
The landscape of m6A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance
Authors: Chaoqi Zhang, Zhihui Zhang, Zhen Zhang, Yuejun Luo, Peng Wu, Guochao Zhang, Liyan Xue, Qingpeng Zeng, Lide Wang, Zhaoyang Yang, Hua Zeng, Bo Zheng, Fengwei Tan, Qi Xue, Shugeng Gao, Nan Sun, Jie He
Journal: Molecular Cancer (2021)
1423P Genomic landscape in advanced gastric cancer from real-world data (RWD) of clinical genomic testing
Authors: H. Yamamoto, R. Oikawa, H. Takeda, K. Umemoto, A. Doi, Y. Horie, T. Ogura, T. Mizukami, N. Izawa, J.A. Moore, E. Sokol, Y. Sunakawa
Journal: Annals of Oncology (2021)
1585P COVID-19 cancer patients outcomes in an intensive care setting: A case-control study
Authors: R. Ranchor, N. Pereira, R. Medeiros, R. Romão, M.J. Ramos, A.S. Mendes, I. Peixoto, M. Magalhães, A. Marinho, A. Araújo
Journal: Annals of Oncology (2021)
1109P The psychological impact of COVID-19 pandemic on patients with NETs: Between resilience and vulnerability
Authors: E. Lauricella, M. Cives, V. Felici, A. Bracigliano, None S. lamia, R. Lippolis, B. Amoruso, E. Pelle, C. Esposto, B. Mandriani, G. Di Lorenzo, O. Clemente, C.G. Porta, S. Tafuto
Journal: Annals of Oncology (2021)
508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)
Authors: M.P. Ducreux, A. Parzy, M. Ben Abdelghani, J. Martin-Babau, D. Tougeron, D. Botsen, J. Taieb, D. Pannier, F. Khemissa, J. Viaud, A.L. Villing, O. Bouche, A. Peytier, H. Alexandre, F. Garic, M-L. Tanguy, J-B. Bachet
Journal: Annals of Oncology (2021)
A micro/nano-biomimetic coating on titanium orchestrates osteo/angio-genesis and osteoimmunomodulation for advanced osseointegration
Authors: Long Bai, Peiru Chen, Ya Zhao, Ruiyue Hang, Xiaohong Yao, Bin Tang, Changsheng Liu, Yin Xiao, Ruiqiang Hang
Journal: Biomaterials (2021)
1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial
Authors: M.C. Piccirillo, L. Bonanno, M.C.C. Garassino, C. Dazzi, L. Cavanna, G. Esposito, M.A. Burgio, F. Rosetti, S. Rizzato, L. Arenare, P. Gargiulo, R. Di Liello, F. De Marinis, L. Crinò, F. Morgillo, F. Ciardiello, N. Normanno, C. Gallo, C. Gridelli, A. Morabito
Journal: Annals of Oncology (2021)
Retinal neuroprotection by controlled release of a VCP inhibitor from self-assembled nanoparticles
Authors: Merve Sen, Md Al-Amin, Eva Kicková, Amir Sadeghi, Jooseppi Puranen, Arto Urtti, Paolo Caliceti, Stefano Salmaso, Blanca Arango-Gonzalez, Marius Ueffing
Journal: Journal of Controlled Release (2021)
144P A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer
Authors: W. Janni, J. Huober, S. Huesmann, C. Pipinikas, T. Braun, V. Müller, G. Marsico, A. Fink, P. Freire-Pritchett, K. Koretz, C. Knape, A. de Gregorio, B. Rack, T.W.P. Friedl, L. Wiesmueller, P. Möller, K. Howarth, K. Pantel, N. Rosenfeld
Journal: Annals of Oncology (2021)
432P Pembrolizumab (pembro) for previously treated, microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
Authors: D.T. Le, L. Diaz, T.W. Kim, E. Van Cutsem, R. Geva, D. Jäger, H. Hara, M. Burge, B. O'Neil, P. Kavan, T. Yoshino, R. Guimbaud, H. Taniguchi, E. Elez, S-E. Al-Batran, P. Boland, Y. Cui, P. Leconte, P. Marinello, T. André
Journal: Annals of Oncology (2021)
1645P Group psychotherapy in young female cancer patients during COVID-19 pandemic
Authors: M. Abuladze, T. Cholikidze, T. Esakia, S. Tsitsilashvili, N. Koiava, N. Jokhadze, M. Katcharava, N. Otkhozoria, E. Mariamidze, T. Melkadze, M. Maglakelidze, K. Saganelidze
Journal: Annals of Oncology (2021)
901P Relationship between p16 and tumor-infiltrating lymphocytes in Peruvian patients with head and neck cancer
Authors: C.A. Castaneda, M. Castillo Garcia, L.A. Bernabe, J. Sanchez, K. Tello, R. Alatrsita, L. Villa, L. Sichero, J. Enciso, H. Guerra
Journal: Annals of Oncology (2021)
210P TACH101, a first-in-class KDM4 inhibitor for treatment of triple-negative breast cancer
Authors: F.G. Perabo, S. Yoo, C. Chandhasin, J.R. Del Rosario, Y.K. Chen, E. Filvaroff, J. Stafford, S. Quake, M. Clarke
Journal: Annals of Oncology (2021)
Cancer immunogenic cell death via photo-pyroptosis with light-sensitive Indoleamine 2,3-dioxygenase inhibitor conjugate
Authors: Yang Lu, Feng Xu, Yang Wang, Chao Shi, Yuzhuo Sha, Guangli He, Qichao Yao, Kun Shao, Wen Sun, Jianjun Du, Jiangli Fan, Xiaojun Peng
Journal: Biomaterials (2021)
BRD4 orchestrates genome folding to promote neural crest differentiation
Authors: Ricardo Linares-Saldana, Wonho Kim, Nikhita A. Bolar, Haoyue Zhang, Bailey A. Koch-Bojalad, Sora Yoon, Parisha P. Shah, Ashley Karnay, Daniel S. Park, Jennifer M. Luppino, Son C. Nguyen, Arun Padmanabhan, Cheryl L. Smith, Andrey Poleshko, Qiaohong Wang, Li Li, Deepak Srivastava, Golnaz Vahedi, Gwang Hyeon Eom, Gerd A. Blobel, Eric F. Joyce, Rajan Jain
Journal: Nature Genetics (2021)
Abstract 12767: The Association Between Serum Calcium Levels and Short-Term Mortality in Chronic Heart Failure Patients
Authors: Anne-Sofie Caroline Jenen, Christoffer Polcwiartek, Peter Søgaard, Rikke N Mortensen, Line Davidsen, Mette Aldahl, Matilde A Eriksen, Kristian Kragholm, Christian Torp-Pedersen, Steen M Hansen
Journal: Circulation (2018)

Background: Patients with chronic heart failure have a vulnerable myocardial function and are susceptible to electrolyte disturbances. In these patients, diuretic treatment is frequently prescribed...
1714P Edmonton symptom assessment system (ESAS)-total care (TC): Development and psychometric validation in Italian language of ESAS-TC in patients undergoing cancer treatment and follow-up
Authors: C.I. Ripamonti, R. Leporati, P. Di Pede, G. De Feo, L. Toffolatti, M. Guglielmo, D. La Carpia, G. Miccinesi, F. Chiesi
Journal: Annals of Oncology (2021)
853P PRAME expression and ImmTAC TCR bispecific sensitivity in acute myeloid leukaemia in the presence and absence of the hypomethylating agent decitabine
Authors: C. Britton-Rivet, J. Houghton, R. Khanolkar, M. Patel, T. Aleksic, M. Vähä-Koskela, A. Benlahrech, D.M. Gascoyne
Journal: Annals of Oncology (2021)
1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study
Authors: S.T.C. Shepherd, A. Fendler, L. Au, F. Byrne, K. Wilkinson, M. Wu, A.M. Schmitt, N. Joharatnam-Hogan, B. Shum, L. Del Rosario, K. Edmonds, E. Carlyle, E. Nicholson, M. Howell, C. Swanton, S. Walker, G. Kassiotis, R. Wilkinson, J. Larkin, S. Turajlic
Journal: Annals of Oncology (2021)
919P Survival impact of nutritional status of locally advanced head and neck cancer squamous cell carcinoma (HNSCC) patients treated with chemoradiotherapy: A prospective observational study
Authors: R. Meesart, P.C. Shantavasinkul, N. Taonam, N. Sankaseam, S. Aiempradit, P. Pattaranutaporn, C. Jiarpinitnun, N. Ngamphaiboon
Journal: Annals of Oncology (2021)
Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients
Authors: Maria Prendecki, Tina Thomson, Candice L Clarke, Paul Martin, Sarah Gleeson, Rute Cardoso De Aguiar, Helena Edwards, Paige Mortimer, Stacey McIntyre, Donald Mokreri, Alison Cox, Graham Pickard, Liz Lightstone, David Thomas, Stephen P McAdoo, Peter Kelleher, Michelle Willicombe
Journal: The Lancet (2021)